Latest Insider Transactions at Alnylam Pharmaceuticals, Inc. (ALNY)
This section provides a real-time view of insider transactions for Alnylam Pharmaceuticals, Inc. (ALNY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ALNYLAM PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ALNYLAM PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 29
2024
|
Amy W Schulman Director |
SELL
Open market or private sale
|
Direct |
21,700
-30.62%
|
$3,211,600
$148.97 P/Share
|
May 29
2024
|
Amy W Schulman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+49.89%
|
$1,980,000
$66.83 P/Share
|
Mar 01
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,754
+24.84%
|
-
|
Mar 01
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,741
+22.14%
|
-
|
Mar 01
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
4,751
+26.15%
|
-
|
Mar 01
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,751
+32.24%
|
-
|
Feb 29
2024
|
Phillip A Sharp Director |
SELL
Open market or private sale
|
Direct |
30,000
-56.94%
|
$4,590,000
$153.11 P/Share
|
Feb 29
2024
|
Phillip A Sharp Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
$1,770,000
$59.25 P/Share
|
Feb 28
2024
|
Indrani Lall Franchini EVP, CLO & Secretary |
SELL
Open market or private sale
|
Direct |
329
-1.51%
|
$51,324
$156.35 P/Share
|
Feb 28
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
501
-1.8%
|
$78,156
$156.35 P/Share
|
Feb 28
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
574
-1.27%
|
$89,544
$156.35 P/Share
|
Feb 28
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,932
-1.17%
|
$457,392
$156.35 P/Share
|
Feb 28
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
574
-0.58%
|
$89,544
$156.35 P/Share
|
Feb 27
2024
|
Indrani Lall Franchini EVP, CLO & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
878
+16.44%
|
-
|
Feb 27
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,667
+22.51%
|
-
|
Feb 27
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,908
+17.12%
|
-
|
Feb 27
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,921
+10.39%
|
-
|
Feb 27
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,908
+8.69%
|
-
|
Feb 16
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,030
-4.68%
|
$1,040,440
$148.26 P/Share
|
Feb 16
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,009
-7.06%
|
$149,332
$148.26 P/Share
|
Feb 16
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,007
-1.78%
|
$149,036
$148.26 P/Share
|
Feb 16
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,308
-5.29%
|
$193,584
$148.26 P/Share
|
Feb 15
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,953
+24.53%
|
-
|
Feb 15
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,278
+39.22%
|
-
|
Feb 15
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,278
+14.62%
|
-
|
Feb 15
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
4,295
+33.2%
|
-
|
Feb 02
2024
|
Indrani Lall Franchini EVP, CLO & Secretary |
SELL
Open market or private sale
|
Direct |
1,591
-11.41%
|
$272,061
$171.18 P/Share
|
Feb 01
2024
|
Indrani Lall Franchini EVP, CLO & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
5,175
+50.0%
|
-
|
Dec 27
2023
|
Michael W Bonney Director |
SELL
Open market or private sale
|
Direct |
30,000
-65.18%
|
$5,850,000
$195.0 P/Share
|
Dec 27
2023
|
Michael W Bonney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+39.46%
|
$2,880,000
$96.45 P/Share
|
Aug 07
2023
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
4,166
-18.96%
|
$766,544
$184.52 P/Share
|
Aug 04
2023
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,057
-1.79%
|
$754,602
$186.95 P/Share
|
Aug 04
2023
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,460
-3.18%
|
$643,560
$186.95 P/Share
|
Aug 04
2023
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
3,461
-5.39%
|
$643,746
$186.95 P/Share
|
Aug 04
2023
|
Akshay Vaishnaw President |
SELL
Open market or private sale
|
Direct |
4,057
-2.66%
|
$754,602
$186.95 P/Share
|
Aug 03
2023
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,941
+10.75%
|
-
|
Aug 03
2023
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,627
+17.82%
|
-
|
Aug 03
2023
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
7,627
+27.19%
|
-
|
Aug 03
2023
|
Akshay Vaishnaw President |
BUY
Grant, award, or other acquisition
|
Direct |
8,941
+15.34%
|
-
|
Aug 03
2023
|
Michael W Bonney Director |
SELL
Open market or private sale
|
Direct |
6,448
-4.67%
|
$1,186,432
$184.7 P/Share
|
Aug 02
2023
|
Michael W Bonney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
22,477
+50.0%
|
-
|
Apr 28
2023
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
2,455
-7.01%
|
$486,090
$198.55 P/Share
|
Apr 27
2023
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
977
-1.58%
|
$189,538
$194.96 P/Share
|
Apr 27
2023
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,839
-4.6%
|
$356,766
$194.96 P/Share
|
Apr 27
2023
|
Akshay Vaishnaw President |
SELL
Open market or private sale
|
Direct |
2,392
-2.46%
|
$464,048
$194.96 P/Share
|
Apr 27
2023
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,476
-10.86%
|
$286,344
$194.96 P/Share
|
Apr 27
2023
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,615
-4.32%
|
$1,477,310
$194.96 P/Share
|
Apr 26
2023
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,277
+20.53%
|
-
|
Apr 26
2023
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
4,294
+33.2%
|
-
|
Apr 26
2023
|
Akshay Vaishnaw President |
BUY
Grant, award, or other acquisition
|
Direct |
5,312
+20.75%
|
-
|